High-SETD8 inactivates p53 in neuroblastoma.
作者信息
Veschi Veronica, Thiele Carol J
机构信息
Cell and Molecular Biology Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
出版信息
Oncoscience. 2017 Apr 14;4(3-4):21-22. doi: 10.18632/oncoscience.344. eCollection 2017 Mar.
Abstract
摘要
相似文献
1
High-SETD8 inactivates p53 in neuroblastoma.高表达的SETD8使神经母细胞瘤中的p53失活。
Oncoscience. 2017 Apr 14;4(3-4):21-22. doi: 10.18632/oncoscience.344. eCollection 2017 Mar.
2
Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.表观遗传小干扰RNA和化学筛选确定SETD8抑制作为高危神经母细胞瘤中p53激活的治疗策略。
Cancer Cell. 2017 Jan 9;31(1):50-63. doi: 10.1016/j.ccell.2016.12.002.
3
Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors.赖氨酸甲基转移酶SETD8抑制剂的研发进展
ChemMedChem. 2016 Aug 19;11(16):1680-5. doi: 10.1002/cmdc.201600272. Epub 2016 Jul 14.
4
The PPARγ-SETD8 axis constitutes an epigenetic, p53-independent checkpoint on p21-mediated cellular senescence.PPARγ-SETD8轴构成了一个在p21介导的细胞衰老过程中不依赖p53的表观遗传检查点。
Aging Cell. 2017 Aug;16(4):797-813. doi: 10.1111/acel.12607. Epub 2017 May 17.
5
Structure-activity relationship studies of SETD8 inhibitors.SETD8抑制剂的构效关系研究。
Medchemcomm. 2014 Dec;5(12):1892-1898. doi: 10.1039/C4MD00317A.
6
Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase.含SET结构域蛋白8（SETD8）赖氨酸甲基转移酶共价抑制剂的基于结构的设计
J Med Chem. 2016 Nov 10;59(21):9881-9889. doi: 10.1021/acs.jmedchem.6b01244. Epub 2016 Nov 2.
7
The emerging role of lysine methyltransferase SETD8 in human diseases.赖氨酸甲基转移酶SETD8在人类疾病中的新作用。
Clin Epigenetics. 2016 Sep 22;8:102. doi: 10.1186/s13148-016-0268-4. eCollection 2016.
8
9
Downregulation of SETD8 by miR-382 is involved in glioma progression.miR-382介导的SETD8下调参与胶质瘤进展。
Pathol Res Pract. 2018 Mar;214(3):356-360. doi: 10.1016/j.prp.2018.01.004. Epub 2018 Jan 31.
10
[Preparation and application of rabbit anti-mouse Setd8 polyclonal antibody].兔抗小鼠Setd8多克隆抗体的制备与应用
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2017 Feb;33(2):246-51.
引用本文的文献
1
Editorial: Epigenetics and stem cell therapy in cancer and diseases.社论：癌症与疾病中的表观遗传学和干细胞疗法
Front Mol Med. 2025 May 16;5:1621093. doi: 10.3389/fmmed.2025.1621093. eCollection 2025.
2
Emerging Trends in Neuroblastoma Diagnosis, Therapeutics, and Research.神经母细胞瘤诊断、治疗与研究的新趋势
Mol Neurobiol. 2025 May;62(5):6423-6466. doi: 10.1007/s12035-024-04680-w. Epub 2025 Jan 13.
3
Targeting epigenetic alterations in cancer stem cells.针对癌症干细胞中的表观遗传改变。
Front Mol Med. 2022 Sep 20;2:1011882. doi: 10.3389/fmmed.2022.1011882. eCollection 2022.
4
Novel insights into cancer stem cells targeting: CAR-T therapy and epigenetic drugs as new pillars in cancer treatment.癌症干细胞靶向治疗的新见解：嵌合抗原受体T细胞（CAR-T）疗法和表观遗传药物成为癌症治疗的新支柱
Front Mol Med. 2023 May 18;3:1120090. doi: 10.3389/fmmed.2023.1120090. eCollection 2023.
5
Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models.针对 ALK 异常神经母细胞瘤的联合治疗在临床前模型中的研究。
Clin Cancer Res. 2023 Apr 3;29(7):1317-1331. doi: 10.1158/1078-0432.CCR-22-2274.
6
Bioinformatics Analysis of Neuroblastoma miRNA Based on GEO Data.基于GEO数据的神经母细胞瘤微小RNA的生物信息学分析
Pharmgenomics Pers Med. 2021 Jul 13;14:849-858. doi: 10.2147/PGPM.S312171. eCollection 2021.
7
Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options.癌症干细胞与神经母细胞瘤：特征及治疗靶向选择
Front Endocrinol (Lausanne). 2019 Nov 19;10:782. doi: 10.3389/fendo.2019.00782. eCollection 2019.
8
Targeting the Chromosomal Passenger Complex Subunit INCENP Induces Polyploidization, Apoptosis, and Senescence in Neuroblastoma.靶向染色体乘客复合物亚单位 INCENP 诱导神经母细胞瘤多倍体形成、凋亡和衰老。
Cancer Res. 2019 Oct 1;79(19):4937-4950. doi: 10.1158/0008-5472.CAN-19-0695. Epub 2019 Aug 15.
9
Microenvironment in neuroblastoma: isolation and characterization of tumor-derived mesenchymal stromal cells.神经母细胞瘤中的微环境：肿瘤衍生的间充质基质细胞的分离和鉴定。
BMC Cancer. 2018 Nov 27;18(1):1176. doi: 10.1186/s12885-018-5082-2.
10
Molecularly Targeted Therapy for Neuroblastoma.神经母细胞瘤的分子靶向治疗
Children (Basel). 2018 Oct 15;5(10):142. doi: 10.3390/children5100142.
本文引用的文献
1
Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma.表观遗传小干扰RNA和化学筛选确定SETD8抑制作为高危神经母细胞瘤中p53激活的治疗策略。
Cancer Cell. 2017 Jan 9;31(1):50-63. doi: 10.1016/j.ccell.2016.12.002.
2
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.赖氨酸甲基转移酶SETD8的选择性底物竞争性抑制剂的发现。
J Med Chem. 2014 Aug 14;57(15):6822-33. doi: 10.1021/jm500871s. Epub 2014 Jul 25.
3
Low p14ARF expression in neuroblastoma cells is associated with repressed histone mark status, and enforced expression induces growth arrest and apoptosis.神经母细胞瘤细胞中低表达 p14ARF 与组蛋白标记状态受抑制有关，强制表达会导致生长停滞和细胞凋亡。
Hum Mol Genet. 2013 May 1;22(9):1735-45. doi: 10.1093/hmg/ddt020. Epub 2013 Jan 23.
4
Molecular mechanisms of MYCN-dependent apoptosis and the MDM2-p53 pathway: an Achille's heel to be exploited for the therapy of MYCN-amplified neuroblastoma.MYCN 依赖性细胞凋亡和 MDM2-p53 通路的分子机制：神经母细胞瘤中 MYCN 扩增的治疗靶点
Front Oncol. 2012 Oct 12;2:141. doi: 10.3389/fonc.2012.00141. eCollection 2012.
5
Histone lysine methyltransferase SETD8 promotes carcinogenesis by deregulating PCNA expression.组蛋白赖氨酸甲基转移酶 SETD8 通过调节 PCNA 表达促进肿瘤发生。
Cancer Res. 2012 Jul 1;72(13):3217-27. doi: 10.1158/0008-5472.CAN-11-3701. Epub 2012 May 3.
6
The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1.HMGA1 原癌基因在癌症中经常失调，是 E2F1 的转录靶标。
Mol Carcinog. 2013 Jul;52(7):526-34. doi: 10.1002/mc.21887. Epub 2012 Mar 2.
7
Modulation of p53 function by SET8-mediated methylation at lysine 382.SET8介导的赖氨酸382甲基化对p53功能的调控
Mol Cell. 2007 Aug 17;27(4):636-46. doi: 10.1016/j.molcel.2007.07.012.
8
The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.p53调控基因MDM2是神经母细胞瘤中MYCN的直接转录靶点。
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):731-6. doi: 10.1073/pnas.0405495102. Epub 2005 Jan 11.
Zotero 插件